Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II

Publication date: June 2021Source: Molecular Genetics and Metabolism Reports, Volume 27Author(s): Ryuji Yamamoto, Eiji Yoden, Noboru Tanaka, Masafumi Kinoshita, Atsushi Imakiire, Tohru Hirato, Kohtaro Minami

Source: Molecular Genetics and Metabolism Reports - April 19, 2021 Category: Genetics & Stem Cells Source Type: research